Apogee Therapeutics

APGE

Market cap $10.1B

Big Pharma has a $300 billion problem, and biotech developers with promising drugs are becoming the fix. Major drugmakers are spending at a pace not seen since 2019 to replace medicines that will soon lose patent protection.

MILWAUKEE, July 02, 2026 (GLOBE NEWSWIRE) -- Ademi LLP is investigating Apogee (NASDAQ: APGE) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with CRH.

LLY, ABBV, BIIB and JNJ hit new 52-week highs as biotech rallies, with company-specific pipeline, approvals and deal activity adding momentum.

Shares of AbbVie, Eli Lilly and Johnson & Johnson were on track to hit all-time highs Friday, in the latest signal that investor appetite for the biopharmaceutical sector is back.

After a sweeping semi-annual rebalance, the biotech index underlying the ALPS Medical Breakthroughs ETF (SBIO) gained over 10% in just six trading days beginning June 18. Key Takeaways: SBIO's underlying index gained 10.01% in six trading days following its June 18 semi-annual rebalance.

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Apogee Therapeutics, Inc. (NasdaqGM: APGE) to AbbVie (NYSE: ABBV). Under the terms of the proposed transaction, shareholders of Apogee will receive $135.11 in cash for each share of Apogee that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequa.

In this week's edition of InnovationRx, we look at AbbVie's new megadeal, an agentic AI startup saving Medicare $2 million a week, how new student loan rules could degrade healthcare and more. To get it in your inbox, subscribe here.

On June 22, 2026, Apogee Therapeutics shares surged as investors reacted to AbbVie's proposed acquisition terms.

NEW YORK, June 22, 2026 /PRNewswire/ -- Class Action Attorney  Juan Monteverde  with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Apogee Therapeutics, Inc. (NASDAQ: APGE ) related to its sale to AbbVie Inc. Under the terms of the proposed transaction, Apogee shareholders are expected to receive $135.11 per share in cash.

U.S. stocks were higher, with the Dow Jones index gaining more than 200 points on Monday.